Thymidine phosphorylase (TP), also known as “platelet‐derived endothelial cell growth
factor”(PD‐ECGF), is an enzyme, which is upregulated in a wide variety of solid tumors …

Thymidine phosphorylase (TP) is often induced in the tumour microenvironment by
physiological and chemical stress. Its induction protects cells from apoptosis and helps cell …

Background Multicomponent therapeutics offer bright prospects for the control of complex
diseases in a synergistic manner. However, finding ways to screen the synergistic …

Cancer is an increasingly recognized problem associated with immunosuppression. Recent
reports, however, suggest that the immunosuppressive agent rapamycin has anti-cancer …

An injectable formulation of rapamycin was prepared using amphiphilic block co-polymer
micelles of poly (ethylene glycol)-b-poly (ε-caprolactone)(PEG–PCL). Drug-loaded PEG …

Tumor lymphangiogenesis is now known to play a causal role in lymph node metastasis,
and thus its inhibition would have great significance for the prevention of lymph node …

Numerous nanocarriers of small molecules depend on either non-specific physical
encapsulation or direct covalent linkage. In contrast, this manuscript explores an alternative …

Therapeutic strategies that target and disrupt the already-formed vessel networks of growing
tumors are actively pursued. The goal of these approaches is to induce a rapid shutdown of …

Thymidine phosphorylase (TP), an enzyme involved in pyrimidine metabolism, is identical
with an angiogenic factor, platelet‐derived endothelial cell growth factor (PD‐ECGF). TP is …

The mammalian target of rapamycin (mTOR) is a controller of cell growth with multiple
effects on cancer development and progression. Being closely linked to key oncogenic …